Meng Fan-Jie, Guo Feng, Sun Zhao-Nan, Wang Shu-Jun, Yang Chun-Rui, Wang Chun-Yang, Zhang Wen-Cheng, Gao Zhou-Yong, Ji Lin-Lin, Feng Fu-Kai, Guan Zhi-Yu, Wang Guang-Shun
Baodi Clinical College of Tianjin Medical University, Tianjin Baodi Hospital, Tianjin 301800, China.
Department of Endoscopy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.
Immunol Lett. 2021 Sep;237:17-26. doi: 10.1016/j.imlet.2021.06.005. Epub 2021 Jun 27.
To understand the characteristics of DNA methyltransferase 3a (DNMT3a) in thymoma associated Myasthenia Gravis reveal its transcriptional regulator network as while as analyze the effect of DNMT3a on Rel/ nuclear factor-kappaB family (RelA/RelB) and its downstream autoimmune regulatory factor (Aire).
Tissues of 30 patients with thymoma, with or without myasthenia gravis (MG), were collected and the DNMT3a protein expression were evaluated through immunohistochemistry. We performed mRNA expression profiling microarray detection and analysis, and integrated the analysis by constructing protein-protein interaction networks and the integration with other database. We identified molecular difference between low and high DNMT3a in the thymoma by heatmap. We also performed PCR validation in thymoma tissues. The DNMT3a-shRNA plasmid was transfected into TEC cells, and these cells were treated with 5-aza-2-deoxycytidine, a blocker of DNMT3a. After the down-regulation of DNMT3a in TEC cells, the transcript and protein levels of RelA, RelB, Aire, and CHRNA3 were evaluated by western blotting. In addition, changes in gene expression profiles were screened through microarray technology. We performed differential gene analysis in the thymoma cohort by heatmap with R (v.4.3.0) software.
In 30 matched tissue specimens, the expression of DNMT3a protein in thymoma with MG was lower than that in thymoma. Through mRNA expression profiling analysis, we constructed a co-expression network of DNMT3a and found direct interaction between IKZF1 and DNMT3a, and this co-expression relationship was overlappted with Cistrome DB database. We found up-regulation of 149 mRNAs and repression of 177 mRNAs in thymoma with MG compared with thymoma. Gene ontology and pathway analysis show the involvement of a multitude of genes in the mis-regulation of MG-related pathways. RNA interference significantly reduced the level of mRNA of DNMT3a, which proved that plasmid DNMT3a was effective. In comparison to the control group, the levels of DNMT3a, Aire, and CHRNA3 mRNA and protein in TEC cells transfected with DNMT3a-shRNA interference plasmid were significantly decreased, while the expression level of RelA and RelA/RelB was significantly increased.
Our study reveals the DNMT3a-NF-κB pathway has a major effect on MG, and can be used as a marker for diagnosis as well as a target for MG treatment.
了解胸腺瘤相关重症肌无力中DNA甲基转移酶3a(DNMT3a)的特征,揭示其转录调控网络,并分析DNMT3a对Rel/核因子-κB家族(RelA/RelB)及其下游自身免疫调节因子(Aire)的影响。
收集30例胸腺瘤患者(伴或不伴重症肌无力)的组织,通过免疫组织化学评估DNMT3a蛋白表达。进行mRNA表达谱微阵列检测和分析,并通过构建蛋白质-蛋白质相互作用网络以及与其他数据库整合进行综合分析。通过热图确定胸腺瘤中低DNMT3a和高DNMT3a之间的分子差异。我们还在胸腺瘤组织中进行了PCR验证。将DNMT3a-shRNA质粒转染到TEC细胞中,并用DNMT3a的阻断剂5-氮杂-2'-脱氧胞苷处理这些细胞。在TEC细胞中DNMT3a下调后,通过蛋白质印迹法评估RelA、RelB、Aire和CHRNA3的转录本和蛋白水平。此外,通过微阵列技术筛选基因表达谱的变化。我们使用R(v.4.3.0)软件通过热图在胸腺瘤队列中进行差异基因分析。
在30对匹配的组织标本中,伴重症肌无力的胸腺瘤中DNMT3a蛋白表达低于胸腺瘤。通过mRNA表达谱分析,我们构建了DNMT3a的共表达网络,发现IKZF1与DNMT3a之间存在直接相互作用,并且这种共表达关系与Cistrome DB数据库重叠。与胸腺瘤相比,我们发现伴重症肌无力的胸腺瘤中有149种mRNA上调,177种mRNA下调。基因本体论和通路分析表明众多基因参与了重症肌无力相关通路的失调。RNA干扰显著降低了DNMT3a的mRNA水平,这证明质粒DNMT3a是有效的。与对照组相比,用DNMT3a-shRNA干扰质粒转染的TEC细胞中DNMT3a、Aire和CHRNA3的mRNA和蛋白水平显著降低,而RelA和RelA/RelB的表达水平显著增加。
我们的研究揭示DNMT3a-NF-κB通路对重症肌无力有主要影响,可作为诊断标志物以及重症肌无力治疗的靶点。